Comparative Pharmacology
Head-to-head clinical analysis: BUTRANS versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTRANS versus DOLENE.
BUTRANS vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic